OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.
- AIM Chief Executive Officer Thomas K. Equels commented, We are pleased to reach this important step in the development of Ampligen.
- Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of LAPC is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer.
- The Companys Phase 2 study Investigational New Drug (IND) application was previously cleared by the U.S. Food and Drug Administration (FDA).
- The AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma.